1. Introduction {#s0005}
===============

The human gut is a complex ecosystem consisting of 10--100 trillion bacteria. Accumulating evidences suggest that the gut microbiota is associated with metabolic diseases, including obesity[@bib1], insulin resistance[@bib2], [@bib3] and non-alcoholic fatty liver disease (NAFLD)[@bib4]. The drugs for type 2 diabetes (T2D) also produce therapeutic effects by modulating microbial homeostasis[@bib5], [@bib6], [@bib7], [@bib8]. The gut microbiota plays an essential role in the progress of metabolic diseases and is thus a potential drug target.

Dietary nutrients are the main drivers for remodeling the gut microbiota in the daily life of the host. In a cohort study, dietary fiber-induced improvement in glucose metabolism was due to the increased abundance of *Prevotella*[@bib9]. Moreover, the content and diversity of gut microbiota in obese patients are lower than those in lean subjects[@bib10]. Microbiota-derived metabolites, such as bile acids, short chain fatty acids and endotoxin, influence host metabolism by mediating the interaction between the gut and other organs[@bib11]. Recent studies identified a link between the imbalance of intestinal flora and the pathological changes in the metabolism of bile acids in patients suffering from obesity and type 2 diabetes[@bib5], [@bib12], [@bib13]. In the liver, cholesterol is converted to primary bile acids *via* two pathways, with cytochrome P450 family 7 subfamily A member 1 (CYP7A1) as the rate-limiting enzyme in the classic pathway and cytochrome P450 family 7 subfamily B member 1 (CYP7B1) as an important enzyme in the alternative pathway[@bib14]. It was reported that CYP7B1-mediated activation of the alternative pathway exerted metabolic benefits by shaping the gut microbiota and upregulating cold-induced thermogenesis and energy expenditure[@bib15]. Primary bile acids synthesized in the liver are conjugated to taurine and glycine for secretion into the gut. In the gut, the conjugated primary bile acids are deconjugated by bile salt hydrolase (BSH) in gut bacteria flora and 7*α*/*β*-dehydroxylases, converting cholic acid (CA) and chenodeoxycholic acid (CDCA) to secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA), respectively[@bib16].

It is well established that bile acids bind to farnesoid X receptor (FXR), the nuclear receptor that is involved in the control of bile acid homeostasis and the enterohepatic circulation of bile acids and is known to influence multiple metabolic diseases[@bib16], [@bib17]. Activation of intestinal FXR induces fibroblast growth factor 15 (FGF15) to activate hepatic FGF receptor 4/*β*-Klotho signaling to inhibit bile acid synthesis. Notably, recent studies in mice demonstrated that tauro-*β*-muricholic acid (T-*β*MCA) antagonizes intestinal FXR, inhibiting the FXR-FGF15 axis to influence hepatic bile acid and cholesterol metabolism[@bib18], [@bib19], [@bib20], and that inhibition or ablation of intestinal FXR prevented obesity-related metabolic dysfunction in high-fat diet (HFD)-fed and genetically obese mice[@bib21], [@bib22], [@bib23]. However, there are many differences in the bile acid composition between humans and mice, because humans only produce CA and CDCA in the liver whereas mice also produce ursodeoxycholic acid (UDCA) which therefore should be considered as primary bile acid in mice. Intestinal FXR signaling induces FGF15 in mice but FGF19 in humans, with a different regulation of CYP7A1 and cytochrome P450 family 8 subfamily B member 1 (CYP8B1)[@bib21], thus revealing the limitation of translational applications of studies performed in mouse models. Compared with mice, the hamster is considered to be a more appropriate model for studies of metabolic diseases[@bib24]. Notably, lipid metabolism in hamsters is more similar to that in humans, including the production of HFD-induced high plasma triglycerides, the levels of high cholesterol ester transfer protein (CETP) and very low-density lipoprotein (VLDL), and the specific apolipoprotein B (ApoB) expression in the intestine[@bib25], [@bib26]. The HFD-fed golden Syrian hamster model has been used as an animal model of insulin resistance, hepatic steatosis and dyslipidemia, as hamsters have similar lipid profiles to human and are predisposed to HFD-induced hyperlipidemia[@bib27], [@bib28], [@bib29]. Collectively, the hamster is a more ideal animal model to study the pathogenesis and pharmacological interventions of human diet-related metabolic diseases. In the current study, the metabolic phenotypes, bile acid metabolism and FXR signaling were examined after the ablation of the gut microbiota in hamsters.

2. Material and methods {#s0010}
=======================

2.1. Animals {#s0015}
------------

Golden Syrian hamsters were purchased from the Beijing Vital River Laboratory Animal Technology Co., Ltd. Six- to eight-week-old male hamsters were housed in a standard SPF environment (12 h daylight cycle, lights off at 18:00). The hamsters were divided into two groups and given 0.5% CMC-Na (Sigma, St. Louis, MO, USA) or an antibiotic cocktail suspended in 0.5% CMC-Na by gavage twice a week under a 60% high-fat diet (D12492, Research Diet, New Brunswick, NJ, USA) treatment for 4 weeks. The combined antibiotics were consisted of vancomycin (50 mg/kg, Sigma), metronidazole (100 mg/kg, Sigma), kanamycin (100 mg/kg, Sigma) and ampicillin (100 mg/kg, Sigma). The antibacterial spectrum of each antibiotic is as follows (data from Antimicrobe.org):

Vancomycin: coagulase negative *Staphylococci, Streptococcus* spp., *Streptococcus pneumoniae*, *Staphylococcus aureus* (vancomycin susceptible), *Enterococcus* spp. (vancomycin-susceptible)*, Clostridium* spp., *Corynebacterium jeikeium*, *Listeria monocytogenes*, and *Actinomyces*.

Metronidazole: anaerobic Gram-negative bacilli including *Bacteroides species*, *Prevotella* spp.; *Fusobacterium* spp., *Porphyromonas* spp.; anaerobic Gram-positive bacilli including *Clostridium* spp.; Protozoa including *Blastocystis hominis*, *Entamoeba histolytica*, *Giardia lamblia*, and *Trichomonas vaginalis*; *Anaerobic cocci* including *Peptostreptococcus species*, *Veillonella species*.

Kanamycin: *Proteus species* (both indole-positive and indole-negative), *E. coli*, *Enterobacter aerogenes, Serratia marcescens, Klebsiella pneumoniae,* and *Acinetobacter species*.

Ampicillin: Gram-positive including *Enterococcus* spp., *Streptococcus* spp., and *Listeria monocytogenes*; Gram-negative including *Haemophilus influenzae*, *Salmonella* spp., *E. coli*, *Proteus mirabilis*, and *Shigella* spp.

Body weights and food intakes were recorded once a week. Glucose tolerance tests and insulin tolerance tests were conducted during 4th week. The hamsters were sacrificed after 4-h fasting at the end of the 4th week. All animal experiment protocols were approved by the Animal Care and Use Committee of Peking University (Beijing, China).

2.2. Metabolic assays {#s0020}
---------------------

For the glucose tolerance test, the hamsters were fasted for 16 h overnight. The blood glucose at different time points (0, 15, 30, 60, 90 and 120 min) was measured with an Accu-Check glucometer (Bayer, Leverkusen, Germany) before and after glucose (2.5 g/kg) challenge. The insulin tolerance test was carried out after fasting for 6 h. Blood glucose was measured before (0 min) and after (15, 30, 60 and 90 min) intraperitoneal injections of insulin (1.5 UI/kg). Blood glucose levels during glucose and insulin tolerance tests were detected using blood from the tails. Blood samples were collected after fasting for 4 h to measure fasting blood glucose and insulin (Insulin ELISA kit, Alpco, Salem, OR, USA) levels. HOMA-IR was calculated according to Eq. [(1)](#eq0005){ref-type="disp-formula"} to assess glucose homeostasis in hamsters.$${HOMA\text{\{\textbackslash hbox\{-\}\}}IR} = {Fasting\mspace{6mu} blood\mspace{6mu} glucose\left. \left( mmol/L \right. \right) \times Fasting\mspace{6mu} insulin\left( {\mu UI/mL} \right)/22.5}$$

2.3. Histological analysis {#s0025}
--------------------------

Liver tissues were fixed in 4% paraformaldehyde for 4--6 h, and paraffin sections were cut and stained by hematoxylin and eosin (H&E). Tissues embedded in OCT were cut to obtain liver frozen sections, which were stained by oil red O. A minimum of three discontinuous sections were evaluated for each sample, with more than three samples per group.

2.4. Lipid measurements {#s0030}
-----------------------

Total triglycerides (TG) and cholesterol (TC) in the liver and plasma were measured (TGKIT and TCKIT, BioSINO, Beijing, China) to evaluate hepatic steatosis and dyslipidemia. The degree of liver injury was estimated based on plasma alanine amino-transferase (ALT) and aspartate transaminase (AST) (ALT/GPTKIT and AST/GOTKIT, BioSINO, Beijing, China).

2.5. Real-time PCR analysis {#s0035}
---------------------------

The ileal epithelium and liver tissues were frozen in liquid nitrogen and stored at --80 °C The standard chloroform---isopropanol extraction was applied to isolate total RNA from lytic tissues in Trizol reagent. cDNA was synthesized from 2 μg total RNA with a Reverse Transcription Kit (ABM, Richmond, Canada). The relative expression of genes was normalized to 18 S rRNA. All of the primer sequences used in the real-time PCR are listed in [Supporting Information Table S1](#s0095){ref-type="sec"}.

2.6. Sample collection {#s0040}
----------------------

The ileal epithelium was scraped from the lower 1/3 of the small intestine after washing with PBS. Fresh fecal samples were collected from the cecum.

2.7. Bile acid analysis {#s0045}
-----------------------

Ten milligrams each of feces from the cecum, liver and ileal epithelium tissues was dissolved in 100 µL double-distilled water and pulverized. The protein was precipitated with 300 µL methanol containing 0.1% ammonium hydroxide. The supernatants were collected for further analysis, and chlorpropamide (Sigma) was added as an internal standard to quantify bile acid levels. The bile acid concentrations in the supernatants were measured by a UPLC/Synapt G2-Si QTQF MS system (Water Corp, Milford, MA, USA) with an ESI source. An Acquity BEH C18 column (100 mm × 2.1 mm i.d., 1.7 μm, Waters Crop, Milford, MA, USA) was used for chromatographic separation. The column temperature was 45 °C, and the flow rate was 0.4 mL/min. The mobile phase consisted of a mixture of 0.1% formic acid in water and 0.1% formic acid in acetonitrile. A gradient elution was conducted, and MS detection proceeded in the negative mode. A mass range of *m*/*z* 50 to 850 was acquired.

2.8. Data analysis {#s0050}
------------------

GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. The sample sizes were determined by power analysis using StatMate version 2.0 (GraphPad Software, San Diego, CA, USA). Experimental data were shown as the mean±SEM. The investigators involved in this study were not completely blinded in the animal experiments during sample collection and analysis. No data were excluded from the data analysis. A two-tailed unpaired Student׳s *t*-test was used for all comparisons of the hamster-related experiments. *P* values of less than 0.05 were considered significant.

3. Results {#s0055}
==========

3.1. Antibiotic treatment alleviated hepatic steatosis, inflammation and glucose intolerance in HFD-fed hamsters {#s0060}
----------------------------------------------------------------------------------------------------------------

To explore the role of gut microbiota in influencing obesity-related diseases, hamsters under HFD treatment were treated with vehicle or antibiotic cocktail by gavage for four weeks. In antibiotic-treated hamsters, the liver weights and the liver weight to body weight ratios were both reduced ([Fig. 1](#f0005){ref-type="fig"}A and B). H&E and oil red O staining revealed a reduced accumulation of lipids in the liver of antibiotic-treated hamsters compared with the vehicle ([Fig. 1](#f0005){ref-type="fig"}C and D). Moreover, antibiotic treatment significantly decreased hepatic and plasma triglyceride levels ([Fig. 1](#f0005){ref-type="fig"}E and F). Consistent with that, qPCR analysis indicated that lipid synthesis in the liver was downregulated in antibiotic-treated hamsters, while lipid uptake and oxidation had no changes ([Fig. 1](#f0005){ref-type="fig"}G). The reduced levels of plasma alanine aminotransferase (ALT) and aspartate transaminase (AST) further demonstrated the improvement in the liver injury after antibiotic treatment ([Fig. 1](#f0005){ref-type="fig"}H and I). Above results suggested that antibiotic treatment had beneficial effects in reducing hepatic lipid accumulation and liver injury under 60% HFD treatment in hamsters.Figure 1Ablation of gut microbiota protects from obesity-induced hepatic steatosis and liver injury in hamsters. The hamsters were fed a 60% high-fat diet and given vehicle or antibiotics for 4 weeks (*n*=5 hamsters/group). (A) The liver weight. (B) The ratio of liver weight to body weight. (C) Representative H&E (upper panel) and oil red O (lower panel) staining of liver sections of the two groups. Scale bars: 200 μm (3 images/hamster). (D) Steatosis degree (the ratio of vacuolar area to whole area in one image, 3 images/hamster). (E) Hepatic triglycerides. (F) Plasma triglycerides. (G) The relative expression of genes involved in fatty acid synthesis, uptake and oxidation in the liver. (H) Plasma ALT levels. (I) Plasma AST levels. Data are presented as the mean±SEM. ^\*^*P\<*0.05, ^\*\*^*P\<*0.01 *versus* vehicle by two-tailed Student׳s *t*-test.Fig. 1

The glucose tolerance test (GTT) and insulin tolerance test (ITT) revealed that glucose intolerance and insulin resistance were substantially improved after antibiotic treatment ([Fig. 2](#f0010){ref-type="fig"}A--C). Antibiotic-treated hamsters displayed lower fasting serum insulin level and HOMA-IR than the vehicle ([Fig. 2](#f0010){ref-type="fig"}D--F). Antibiotic-treated hamsters were resistant to HFD-induced body weight gain ([Supporting Information Fig. S1A](#s0095){ref-type="sec"} and B). The fat mass and fat weight/body weight ratios of subcutaneous white adipose tissue (sWAT) and epididymal white adipose tissue (eWAT) were markedly decreased after antibiotic treatment, while there were no differences in brown adipose tissue ([Fig. 2](#f0010){ref-type="fig"}G and [Fig. S1C](#s0095){ref-type="sec"}). It was reported that cold-induced microbial alteration was beneficial for beiging in the sWAT, resulting in an ameliorative metabolic phenotype in mice[@bib30]. Indeed, the mRNA levels of thermogenic genes, such as *Ucp1* and *Elovl3*, were significantly elevated in the sWAT of antibiotic-treated hamsters ([Fig. 2](#f0010){ref-type="fig"}H). Food intake remained unchanged between vehicle- and antibiotic-treated hamsters ([Fig. S1](#s0095){ref-type="sec"}D). The above results highlighted the effects of gut microbiota on the progress of HFD-induced metabolic disorders in hamsters.Figure 2Ablation of gut microbiota improves obesity-induced insulin resistance in hamsters. The hamsters were fed a 60% high-fat diet and given vehicle or antibiotics for 4 weeks (*n*=5 hamsters/group). On the fourth week, glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed. (A) GTT; (B) Area under the curve (AUC); (C) ITT. (D) Fasting glucose levels; (E) Fasting insulin levels; (F) HOMA-IR; (G) The ratios of fat mass to body weight in subcutaneous adipose tissue (sWAT), epididymal adipose tissue (eWAT) and brown adipose tissue (BAT); (H) The relative expression of thermogenic gene mRNAs in the sWAT. Data are presented as the mean±SEM, *n*=5 hamsters/group. ^\*^*P\<*0.05, ^\*\*^*P\<*0.01 *versus* vehicle by two-tailed Student׳s *t*-test.Fig. 2

3.2. Modulation of bile acid synthesis in the liver by antibiotics {#s0065}
------------------------------------------------------------------

Bile acids are mainly synthesized in the liver *via* both classical and alternative pathways. The classical pathway is initiated by the rate-limiting enzyme CYP7A1, which accounts for approximately 75% of bile acid production under physiological conditions. CYP7B1 is mainly involved in the alternative pathway[@bib31]. Moreover, the formation of bile acids involves multiple enzymes, including cytochrome P450 family 27 subfamily A member 1 (CYP27A1) and CYP8B1 ([Fig. 3](#f0015){ref-type="fig"}A). Recent studies revealed that the expression of CYP7A1, CYP27A1 and CYP7B1 was influenced by the gut microbiota in mice[@bib20]. However, it remains unknown whether bile acid synthesis is under microbial regulation in hamsters. There was no significant difference in hepatic content of cholesterol and total primary bile acids in the liver between the two groups ([Fig. 3](#f0015){ref-type="fig"}B and C). Antibiotic treatment significantly decreased glycocholic acid (GCA) levels and significantly increased T*β*MCA levels in liver ([Fig. 3](#f0015){ref-type="fig"}D and E). Alterations in the bile acid composition were associated with metabolic disorders in the clinic. It was reported that the ratio of 12*α*-OH to non-12*α*-OH bile acids (12*α*-OH to non-12*α*-OH BAs) was positively associated with insulin resistance and hyperlipidemia[@bib32] and that the ratio of primary bile acids to secondary bile acids (PBA/SBA) declined in non-alcoholic steatohepatitis (NASH) patients[@bib33]. In antibiotic-treated hamsters, the PBA/SBA ratio was markedly elevated, while there was a decrease in the ratio of 12*α*-OH to non-12*α*-OH BAs ([Fig. 3](#f0015){ref-type="fig"}F and [Supporting Information Fig. S2A](#s0095){ref-type="sec"}). The conjugation of bile acids was not different between the two groups ([Fig. S2B](#s0095){ref-type="sec"}). Furthermore, *Cyp7b1* mRNA was upregulated, while there were no significant changes in the relative expression of *Cyp7a1*, *Cyp27a1* and *Cyp8b1* ([Fig. 3](#f0015){ref-type="fig"}G). According to the hydrophobicity indices of bile acids, DCA, LCA, CA and their conjugates are hydrophobic, while *β*-muricholic acid (*β*MCA) and T*β*MCA are hydrophilic[@bib34]. In hamsters, gut microbiota depletion led to a more hydrophilic bile acid profile, with an elevation of T*β*MCA in the liver.Figure 3Alternative bile acid synthesis in the liver is elevated after antibiotic treatment. The hamsters were fed a 60% high-fat diet and given vehicle or antibiotics for 4 weeks (*n*=5 hamsters/group). (A) Bile acid synthesis in the liver; (B) Hepatic cholesterol; (C) Total primary bile acids in the liver; (D) Primary bile acid profiles in the liver; (E) Primary bile acid composition in the liver; (F) The ratio of 12*α*-OH bile acids to non-12*α*-OH bile acids in the liver \[12*α*-OH/non12*α*-OH BA=(GCA+CA+TCA+GDCA+DCA+TDCA)/(LCA+HDCA+CDCA+UDCA+*β*MCA+GCDCA+GUDCA+TLCA+TUDCA+THDCA+T*β*MCA)\]; (G) The relative expression of genes involved in bile acid synthesis. Data are presented as the mean±SEM, *n*=5 hamsters/group. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 *versus* vehicle by two-tailed Student׳s *t*-test.Fig. 3

3.3. Antibiotic treatment remodeled the bile acid profiles in the gut {#s0070}
---------------------------------------------------------------------

Multiple gut microbiota-derived enzymes are involved in bile acid modification, including deconjugation, transport and 7*α*/*β*-dehydroxylation[@bib5]. CA, CDCA and *β*MCA are produced from conjugated bile acids *via* BSH and are further converted to secondary bile acids after 7*α*/*β*-dehydroxylation ([Supporting Information Fig. S3A](#s0095){ref-type="sec"}). The total ileal bile acid levels did not change after antibiotic treatment ([Fig. 4](#f0020){ref-type="fig"}A). Further metabolomics analysis showed that the levels of ileal and fecal secondary bile acids in the antibiotic-treated group were much lower than those in the vehicle-treated group, which was likely due to the absence of 7*α*/*β*-dehydroxylase activity ([Fig. 4](#f0020){ref-type="fig"}B, C and [Fig. S3C](#s0095){ref-type="sec"}). Consistently, the ratio of PBA/SBA was significantly upregulated by antibiotic treatment ([Fig. 4](#f0020){ref-type="fig"}D and [Fig. S3D](#s0095){ref-type="sec"}). The reduction of total fecal bile acids was probably due to the deficient transformation from primary unconjugated bile acids to secondary bile acids ([Fig. S3B](#s0095){ref-type="sec"}). In the ileum, there was a reduced ratio of unconBA/conBA, with a remarkable accumulation of T*β*MCA ([Fig. 4](#f0020){ref-type="fig"}B, C and E), which was previously identified as an intestinal FXR antagonist in mice[@bib20]. The conjugated bile acids, such as glycochenodeoxycholic acid (GCDCA), GCA and taurocholic acid (TCA), were more abundant in the feces of antibiotic-treated hamsters but there was no increase in the ileum, indicating the excretion of GCDCA, GCA and TCA was elevated after antibiotic treatment ([Fig. S3C](#s0095){ref-type="sec"}). The elevation in ileal T*β*MCA levels might have resulted from the increased CYP7B1-mediated synthesis and the decreased microbial deconjugation.Figure 4Microbial modulation of bile acid metabolism in the gut. (A) Total ileal bile acids; (B) Bile acid levels in the ileum; (C) Bile acid composition in the ileum; (D) The ratio of primary bile acids to secondary bile acids in the ileum; (E) The ratio of unconjugated bile acids to conjugated bile acids in the ileum. Data are presented as the mean±SEM, *n*=5 hamsters/group. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 *versus* vehicle by two-tailed Student׳s *t*-test.Fig. 4

3.4. Antibiotic treatment suppressed intestinal FXR signaling {#s0075}
-------------------------------------------------------------

Inhibition of intestinal FXR exerted a protective role in insulin resistance and hepatic steatosis[@bib22], [@bib35]. T*β*MCA, the antagonist of intestinal FXR in mice, had been found to be markedly increased in the ileum of antibiotic-treated hamsters ([Fig. 3](#f0015){ref-type="fig"}D). In antibiotic-treated hamsters, FXR signaling was selectively suppressed in the gut but not in the liver ([Fig. 5](#f0025){ref-type="fig"}A and B). These results suggested that intestinal FXR inhibition was the potential target of gut microbiota-derived bile acid signaling in the metabolic diseases.Figure 5Intestinal FXR is suppressed in the absence of gut microbiota. (A) The relative abundance of intestinal FXR and its target genes; (B) The mRNA levels of genes in the hepatic FXR signaling. Data are presented as the mean±SEM, *n*=5 hamsters/group. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01 *versus* vehicle by two-tailed Student׳s *t*-test.Fig. 5

4. Discussion {#s0080}
=============

Obesity, type 2 diabetes and non-alcohol fatty liver disease are aspects of metabolic syndrome, which is a major public health problem worldwide[@bib36], [@bib37], [@bib38], [@bib39], [@bib40]. Thermogenesis is considered a therapeutic target for obesity[@bib41]. The progress of metabolic syndrome results from interactions between the gut microbiota and the host[@bib42]. Some of these phenotypes could be transferred to germ-free mice by fecal transplantation from mice or patients[@bib43], [@bib44]. It was also found that the therapeutic effects in clinical treatment were determined by the composition of the gut microbiota in patients[@bib5], [@bib45], [@bib46]. Thus, a more complete understanding of how the gut microbiota influences host metabolism and the development of novel therapeutic approaches are important research priorities. Previous studies demonstrated that mice on an HFD that were treated with antibiotics or tempol displayed reduced hepatic triglyceride accumulation and increased beiging of white adipose tissue. In the present study, another animal model, the golden Syrian hamster, was used to more accurately reflect metabolic dysfunction found in humans. There was an obvious hepatic lipid accumulation after only four weeks of HFD treatment. To evaluate the role of the gut microbiota in the progress of HFD-induced metabolic disorders, the HFD-treated hamsters were given vehicle or antibiotics by gavage twice a week for four weeks. After antibiotic treatment, the body weights and the percent of fat mass showed a significant reduction, accompanied by elevated expression of genes involved in thermogenesis in the sWAT. Furthermore, insulin sensitivity and hepatic steatosis were both ameliorated in the absence of the gut microbiota for hamsters on an HFD as a result of the inhibition of lipid synthesis in the liver.

Bile acids are metabolized in the gut, and the bile acid compositions vary widely among mice and humans. It is interesting to note that glycine-conjugated bile acids are much higher in hamsters than mice, which is more like humans. To further determine the microbial metabolism of bile acids in hamsters, a metabolomics analysis of liver, ileum and feces samples was performed. Due to the upregulated excretion in the feces, there was no significant change in the levels of hepatic and ileal GCDCA. In mice, but not in humans, CDCA is converted into *α*,*β*MCA through the activity of a sterol-6*β*-hydroxylase, cytochrome P450, family 2, subfamily c, polypeptide 70 (CYP2C70), which is expressed in the mouse liver[@bib47]. In hamsters, antibiotic treatment markedly upregulated CYP7B1 expression, leading to a more hydrophilic bile acid composition with an increase in T*β*MCA and a reduction in GCA in the liver. CA feeding was shown to elevate fat absorption and aggravate glucose intolerance[@bib48]. A recent study showed that whole-body *Cyp7a1*-null (*Cyp7a1*^--/--^) mice displayed an improvement of glucose tolerance and insulin sensitivity when fed an HFD[@bib49]. In *Cyp7a1*^--/--^ mice, the T*β*MCA content in bile was observed to increase as a result of CYP7B1 upregulation. T*β*MCA is the most efficacious endogenous FXR antagonist, and inhibition of intestinal FXR signaling was found to improve hepatic steatosis and insulin resistance[@bib8], [@bib22]. According to reported clinical data, hepatic CYP7B1 expression was down-regulated, while CYP7A1 and CYP8B1 expression remained similar in the obese individuals with type 2 diabetes (T2D) compared to health controls[@bib15]. Moreover, cold-induced upregulation of CYP7B1 promoted thermogenesis and energy expenditure by increasing brown and beige adipocytes[@bib15]. Above findings suggested that hepatic CYP7B1 potentially plays a vital role in obesity-related T2D in humans. In germ-free mice, hepatic CYP7A1 enzyme activity was mainly up-regulate[@bib20]. Gut microbiota-induced bile acid synthesis enzymes remodeling in liver differed between mice and humans. Consistent with humans, antibiotic-treated hamsters displayed a higher relative expression level of hepatic *Cyp7b1*, but *Cyp7a1*, *Cyp8b1* and *Cyp27a1* relative mRNA levels remain unchanged. Moreover, hamsters displayed more similarities in bile acids metabolism and composition with human. Collectively, hamsters are more proper animals used for confirming whether modulation of gut microbiota-CYP7B1-bile acids axis is a potential therapeutic strategy for clinical T2D treatment.

In the gut, microbiota-derived enzymes mediated the complex biotransformations of bile acids produced in the liver, including deconjugation, 7-dehydroxylation and oxidation of hydroxyl groups[@bib50]. Bile acid deconjugation is carried out by BSH, expressed in *Lactobacilli*, *Bifidobacteria*, *Clostridium* and *Bacteroides*[@bib51], [@bib52], [@bib53]. Both the preferential reduction of the abundance of *Lactobacilli* and its BSH by the antioxidant tempol and the direct suppression of BSH activity by caffeic acid phenethyl ester (CAPE) resulted in the accumulation of T*β*MCA in the ileum to ameliorate obesity and insulin resistance[@bib35]. Consistently, the levels of T*β*MCA in the ileum and feces were significantly elevated due to the absence of microbial BSH activity after antibiotic treatment in hamsters. Due to the markedly increased excretion in the feces of conjugated bile acids ([Fig. S3C](#s0095){ref-type="sec"}), such as TCA, GCA and GCDCA, the levels of these bile acids were not increased or even slightly decreased in the ileum ([Fig. 4](#f0020){ref-type="fig"}B). Collectively, the accumulation of T*β*MCA was due to both the upregulation of the alternative bile acid synthesis pathway and the inhibition of deconjugation. Secondary bile acids are generated by 7-dehydroxylation with microbial bile acid-inducible (*bai*) gene products. The antibiotic-treated hamsters had an overall reduction in secondary bile acids in the enterohepatic cycle, resulting from the lack of multiple 7-dehydroxylation steps.

FXR is a ligand-activated nuclear receptor that regulates bile acid homeostasis and is primarily expressed in the liver and gut[@bib54]. FXR can be bound by a variety of endogenous bile acids with various affinities, with the potency of FXR activation in reporter gene assays estimated at CDCA\>LCA = DCA[@bib55], [@bib56]. The activated FXR signaling resulted in downregulated bile acid synthesis *via* the inhibition of the expression of CYP7A1[@bib57]. In contrast, the murine conjugated bile acid, T*β*MCA, was proven to be an endogenous FXR antagonist[@bib20], [@bib21]. It was verified that inhibition and knockout of intestinal FXR prevented obesity-related metabolic diseases in mice[@bib21], [@bib22], [@bib23]. In hamsters treated with antibiotics, intestinal FXR signaling (in humans and hamsters) was inhibited, associated with the increased T*β*MCA and the reduced DCA and LCA. However, there was no obvious difference in hepatic FXR signaling between vehicle- and antibiotic-treated hamsters. Thus, this revealed that modulation of bile acids by ablation of the gut microbiota mainly influenced intestinal FXR signaling in hamsters.

5. Conclusions {#s0085}
==============

The present results highlighted that microbial modulation of bile acids was pivotal to regulating obesity-induced metabolic disorders in hamsters. It was suggested that removal of the gut microbiota mainly elevated alternative bile acid synthesis in the liver and suppressed the microbial deconjugation and de-hydroxylation in the gut, leading to increased T*β*MCA and decreased secondary bile acids in the ileum. Remodeling of bile acid profiles due to antibiotic treatment had beneficial effects in improving glucose intolerance and hepatic steatosis. Furthermore, we found that intestinal FXR, but not hepatic FXR, was suppressed after antibiotic treatment in hamsters. These data support the view that intestinal FXR inhibition is a potential target for the clinical treatment of obesity-induced metabolic diseases.
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==================================
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